- Home
- OGEN vs SBFM Comparison
OGEN vs SBFM Comparison
Compare OGEN & SBFM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- OGEN
- SBFM
- Stock Information
- Founded
- OGEN 1996
- SBFM 2006
- Country
- OGEN United States
- SBFM United States
- Employees
- OGEN N/A
- SBFM N/A
- Industry
- OGEN Biotechnology: Pharmaceutical Preparations
- SBFM Biotechnology: Pharmaceutical Preparations
- Sector
- OGEN Health Care
- SBFM Health Care
- Exchange
- OGEN Nasdaq
- SBFM Nasdaq
- Market Cap
- OGEN 4.5M
- SBFM 3.7M
- IPO Year
- OGEN N/A
- SBFM N/A
- Fundamental
- Price
- OGEN $0.34
- SBFM $3.14
- Analyst Decision
- OGEN
- SBFM
- Analyst Count
- OGEN 0
- SBFM 0
- Target Price
- OGEN N/A
- SBFM N/A
- AVG Volume (30 Days)
- OGEN 389.1K
- SBFM 90.8K
- Earning Date
- OGEN 11-07-2024
- SBFM 11-11-2024
- Dividend Yield
- OGEN N/A
- SBFM N/A
- EPS Growth
- OGEN N/A
- SBFM N/A
- EPS
- OGEN N/A
- SBFM N/A
- Revenue
- OGEN $7,466.00
- SBFM $30,481,982.00
- Revenue This Year
- OGEN N/A
- SBFM $86.70
- Revenue Next Year
- OGEN N/A
- SBFM $126.76
- P/E Ratio
- OGEN N/A
- SBFM N/A
- Revenue Growth
- OGEN N/A
- SBFM 109.82
- 52 Week Low
- OGEN $0.29
- SBFM $2.42
- 52 Week High
- OGEN $7.74
- SBFM $660.00
- Technical
- Relative Strength Index (RSI)
- OGEN 37.15
- SBFM 52.62
- Support Level
- OGEN $0.29
- SBFM $2.85
- Resistance Level
- OGEN $0.45
- SBFM $3.05
- Average True Range (ATR)
- OGEN 0.04
- SBFM 0.14
- MACD
- OGEN 0.02
- SBFM 0.03
- Stochastic Oscillator
- OGEN 28.88
- SBFM 85.29
About OGEN Oragenics Inc.
Oragenics Inc is engaged in the research and development of nasal delivery pharmaceutical medications in neurology and fighting infectious diseases. The company's lead product ONP-002 is a fully synthetic, non-naturally occurring neurosteroid, is lipophilic, and can cross the blood-brain barrier to rapidly reduce swelling, oxidative stress and inflammation while restoring proper blood flow through gene amplification.
About SBFM Sunshine Biopharma Inc.
Sunshine Biopharma Inc is a pharmaceutical company offering and researching life-saving medicines in a wide variety of therapeutic areas, including oncology and antivirals. The company is conducting a proprietary drug development program which is comprised of (i) K1.1 mRNA targeted for liver cancer, (ii) SBFM-PL4, PLpro protease inhibitor for SARS Coronavirus infections, and (iii) Adva-27a for pancreatic cancer. The company has two reportable segments: Prescription Generic Pharmaceuticals ("Generic Pharmaceuticals") and Nonprescription Over-The-Counter Products ("OTC Products"). The company generates the majority of its revenue from the Generic Pharmaceuticals segment.